Arcus Biosciences

We have published new preclinical research for AB598, an investigational therapeutic antibody designed to inhibit CD39 enzymatic activity for immuno-oncology. Read more about our latest findings on AB598 here: https://bit.ly/3WmLBzq

We are pleased to announce that Taiho Pharmaceutical Co., Ltd., exercised its options for an exclusive license to another Arcus program. We look forward to this collaboration and the ongoing partnership in Japan and other territories in Asia. Read more: https://bit.ly/3VYtn85

As #CancerImmunotherapyMonth comes to a close, we remain committed to discovering new approaches to cancer immunotherapy that open the door to potential novel treatments for patients in need. At Arcus, we have focused on building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio. Learn from our President Juan Jaen and CMO Dimitry Nuyten about how we are targeting the #adenosineaxis to harness the body’s own immune system to attack and destroy #coloncancer: https://bit.ly/3VbWzJg

We are honored to share that Arcus has been recognized as one of Fortune's 2024 Best Workplaces (small and medium, across industries) in the Bay Area™. At Arcus, we have invested in a strong foundation of smart people and good science, working every day to bring life-changing new therapies to people with cancer. See what makes us a great place to work: https://bit.ly/3VEtSoS #BestWorkplaces, #GPTWcertified

Tomorrow morning, our CEO Terry Rosen and COO Jennifer Jarrett will participate in a fireside chat hosted by Salveen Richter at the Goldman Sachs 45th Annual Global Healthcare Conference. You can watch a livestream of the chat here: https://bit.ly/4bVJNEW

We are pleased to announce the completion of patient enrollment for STAR-221, a Phase 3 study evaluating a domvanalimab-containing regimen in patients with metastatic upper GI cancers. Read more about the announcement here: https://bit.ly/3xcqfgs

Each year, the #ASCO Annual Meeting brings together some of the brightest minds in oncology and fiercest advocates in the cancer community. We leave inspired and renewed in our pursuit of cures for cancer. Cheers to another fantastic year at #ASCO24 – thanks Chicago!

This morning, we shared data at #ASCO24 from our Phase 2 ARC-9 study in metastatic #colorectalcancer, presented by Zev Wainberg in an oral session. Find out more about the data here: https://bit.ly/3R9y792

Today, we shared updated data at #ASCO24 from our Phase 2 EDGE-Gastric study in #stomachcancer. Yelena Janjigian presented the data in a plenary series rapid abstract update session. Read more about the data here: https://bit.ly/4aEgiWI

When words don’t feel like enough, art can be a personal, expressive outlet to share a person’s experience. We are thrilled to partner with the #cancer community and collaborate with digital artist Henry Daubrez to create #PortrAItsofCancer, personalized artwork transcending the boundaries of the spoken word that capture people and the impact of cancer on their lives. Together with our partners Debbie's Dream Foundation: Curing Stomach Cancer, LUNGevity Foundation, and Worth the Wait Charity, people’s stories and portraits will be displayed on a digital gallery, creating a visual legacy of their lives, told through art. Visit our booth #33143 at #ASCO24 to see some of the portraits and follow along to see this gallery come to life at aiportraitsofcancer.com